Universe Pharmaceuticals Inc key statistics and ratios

In fiscal 2025, Universe Pharmaceuticals Inc had return on equity of -7.2%, an operating margin of -16.3%, debt equal to 16.5% of equity and a current ratio of 4.07. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Universe Pharmaceuticals Inc: financial ratios, annual
Fiscal year	2019Sept 2019	2020Sept 2020	2021Sept 2021	2022Sept 2022	2023Sept 2023	2024Sept 2024	2025Sept 2025
Gross margin	40.3%	45.9%	52.8%	54.5%	31.9%	26.4%	35.3%
Operating margin	29.4%	33.4%	28.3%	−17.5%	−12.3%	−34.8%	−16.3%
Net margin	22.7%	24.6%	23.6%	−19.7%	−20.4%	−37.9%	−20.6%
Free-cash-flow margin	39.5%	19.7%	−5.2%	−3.5%	3.3%	−42.2%	−29.8%
Return on equity	61.0%	45.5%	33.4%	−0.0%	−20.8%	−23.8%	−7.2%
Return on assets	—	26.2%	22.9%	−12.2%	<−999%	−25.7%	−5.4%
Asset turnover	—	1.07	0.97	0.62	638.11	0.68	0.26
Current ratio	—	2.91	4.50	3.17	1.84	2.54	4.07
Debt to equity	0.0%	12.7%	9.2%	0.0%	0.0%	12.9%	16.5%
Interest cover (operating income ÷ interest)	75.4x	82.8x	133.8x	n/m	n/m	n/m	n/m
Effective tax rate	21.8%	25.2%	17.2%	—	—	—	—
R&D as % of revenue	1.9%	1.9%	11.4%	19.0%	15.0%	13.2%	3.8%
Capital spending as % of revenue	0.3%	0.2%	0.9%	0.2%	0.1%	0.9%	1.5%
Free cash flow ÷ net income	173.7%	80.2%	−22.1%	—	—	—	—
Dividends ÷ net income	211.9%	—	—	—	—	—	—
Dividends and buybacks ÷ free cash flow	122.0%	—	—	—	—	—	—

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 3 checks passed · September 30, 2025

What it owns · $69.3bn

Short-term assets $53.6bnLonger-term assets $15.7bn

What it owes, and who funded it · $69.3bn

Short-term liabilities $13.2bnLonger-term liabilities $0mShareholders' equity $56.1bn

Short-term assets cover short-term liabilities $53.6bn of assets due within a year against $13.2bn of liabilities due within a year.
Short-term assets cover long-term liabilities $53.6bn short-term assets against $0 of longer-dated liabilities.
More cash than debt Cash or debt not separately reported. Not assessable.
Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
Operating profit covers interest at least five times over Operating income of −$2.9bn against $289m of interest.

From Universe Pharmaceuticals Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: UPC vs VTRS HLN vs UPC BHC vs UPC

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Universe Pharmaceuticals Inc's SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to Universe Pharmaceuticals Inc.